Clinical trial
Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis
NCT02806375 is registered in ClinicalTrials.gov with St. Petersburg State Pavlov Medical University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Graft-versus-host Disease Prophylaxis With Post-transplantation Cyclophosphamide and Ruxolitinib in Patients With Myelofibrosis
- Lead sponsor
- St. Petersburg State Pavlov Medical University
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 31, 2016
- Completion date
- April 30, 2019
- Enrollment
- 20 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.